Νέα έρευνα συνδέει το κάπνισμα με αυξημένο κίνδυνο καρκίνου του μαστού

Εάν είστε γυναίκα μεταξύ 20 και 44 ετών και καπνίζετε ένα πακέτο τσιγάρα /ημέρα επί 10 χρόνια οι μελέτες δείχνουν ότι μάλλον έχετε 60 % περισσότερες πιθανότητες να αναπτύξετε καρκίνο τού μαστού, και μάλιστα ένα συγκεκριμένο υπότυπο αυτού, τον θετικό γιά τούς οιστρογονικούς υποδοχείς.

…μήπως θα ήταν μια καλή ιδέα να το σταματήσετε τωρα?

Δείτε όλο το άρθρο (στα αγγλικά):

ΠΗΓΗ: REUTERS

(Reuters Health) – Young women who smoke may have an increased risk of a common type of breast cancer, according to a new study.

Researchers found that women between 20 and 44 years old who had smoked a pack of cigarettes per day for at least 10 years were 60 percent more likely than those who smoked less to develop so-called estrogen receptor-positive breast cancer.

Smokers were not more likely to develop a less common form of breast cancer known as triple-negative breast cancer, which tends to be more aggressive.

«I think that there is growing evidence that breast cancer is another health hazard associated with smoking,» Dr. Christopher Li told Reuters Health.

Li is the study’s senior author from the Fred Hutchinson Cancer Research Center in Seattle.

Previous research has found links between smoking and breast cancer, Li and his colleagues note in the journal Cancer. The studies looking at breast cancer among younger women have produced conflicting results, however.

They also say there are still questions about whether smoking is linked to an increased risk of some types of breast cancer but not others.

«I think there is a growing appreciation that breast cancer is not just one disease and there are many different subtypes,» Li said. «In this study, we were able to look at the different molecular subtypes and how smoking affects them.»

He and his team analyzed data from young women in the Greater Seattle area who were diagnosed with breast cancer between 2004 and 2010.

Of those women, 778 were diagnosed with the more common estrogen receptor-positive type and 182 had the less common but more aggressive triple-negative type.

The researchers also included information from 938 cancer-free women for comparison.

According to the National Cancer Institute, about one in every eight American women will eventually develop breast cancer – but the risk is lower at younger ages. Only about one in every 227 30-year-old women – or less than half a percent of them – will develop breast cancer before the age of 40, for example.

In this study, young women who had ever smoked were about 30 percent more likely to develop any type of breast cancer, compared to women who had never smoked.

When the researchers looked at each type of breast cancer separately, there was no link between smoking and triple-negative breast cancer.

But women who were recent or current smokers and had smoked for at least 15 years were about 50 percent more likely to have estrogen receptor-positive breast cancer, compared to women who had smoked for fewer years.

And those women who reported smoking at least one pack a day for 10 years were 60 percent more likely to have that type of cancer, compared to lighter smokers.

It could be that some of the substances found in cigarettes act like estrogens, which would promote estrogen receptor-positive breast cancer, the researchers write.

«There are so many different chemicals in cigarette smoke that can have so many kinds of effects,» Li said.

Geoffrey Kabat cautioned that some of the effects found in the new study are small and not clear-cut.

Kabat was not involved with the study, but has researched the effects of smoking on breast cancer risk. He is also an epidemiologist at the Albert Einstein College of Medicine of Yeshiva University in Bronx, New York.

He told Reuters Health the findings of previous studies are not «very consistent.»

«We know smoking is bad for you and the earlier you smoke and the more often you smoke the worse off you’re going to be in terms of many outcomes, but the role of smoking in breast cancer is not clear,» Kabat said. «There may be something going on and it may be a modest effect in some subgroups.»

SOURCE: Cancer, online February 10, 2014.

Medical Journal: Tumor Volumetry in head-and-neck carcinomas

PROGNOSTIC IMPACT OF TUMOR VOLUMETRY IN PATIENTS WITH LOCALLY ADVANCED HEAD-AND-NECK CARCINOMA (NONNASOPHARYNGEAL) TREATED BY RADIOTHERAPY ALONE OR COMBINED RADIOCHEMOTHERAPY IN A RANDOMIZED TRIAL

GEORGE A. PLATANIOTIS, M.D.,* MARIA-EKATERINI THEOFANOPOULOU, M.D.,*
ANNA KALOGERA-FOUNTZILA, M.D.,† AFRODITI HARITANTI, M.D.,† ELISABETA CIULEANOU, M.D.,‡
NICOLAE GHILEZAN, M.D.,‡ NIKOLAOS ZAMBOGLOU, M.D.,§ ATHANASIOS DIMITRIADIS, M.D.,†
IOANNIS SOFRONIADIS, M.D., AND GEORGE FOUNTZILAS, M.D.

*Department of Radiation Oncology, University of Thessalia, Thessalia, Greece; Departments of †Radiology, Radiation Oncology, and Medical Oncology, Aristotle University of Thessaloniki, Thessaloniki, Greece; ‡Department of Radiation Oncology, Cancer Institute Ion Ciricuta, Cluj, Romania; §Strahlenklinik, Staedtische Kliniken Offenbach, Offenbach, Germany

Read or download the journal in PDF | Δείτε ή κατεβάστε την δημοσίευση σε PDF:
 
Tumor Volumetry in head-and-neck carcinomas.pdf

 
Purpose: Tumor volume (TV) is one of the main reported factors determining the outcome of treatment in head-and-neck carcinomas. In this study, the prognostic impact of TV was explored in the context of a randomized trial with the patients assigned to receive standard radiotherapy (RT) alone or RT plus platinum compounds (RT alone, RT plus cisplatin, or RT plus carboplatin).

Methods and Materials: The tumor outlines were traced and digitized on each pretreatment CT slice for each of the 101 patients studied. Taking into account the magnification factor of the scan and CT slice thickness, a computer with specifically designed software calculated the TV in cubic centimeters.

Results: The median overall survival for the whole group of patients was 21.6 months (95% confidence interval, 13.0 –30.2) and the 3-year survival rate was 40%. The addition of platinum compounds to RT (Groups 2 and 3) significantly improved the survival rate (RT alone vs. RT plus cisplatin, hazard ratio 0.36, p  0.002; RT alone vs. RT plus carboplatin, hazard ratio 0.53, p  0.029). In univariate analysis, the most significant parameters for survival were treatment group, total gross tumor volume (TGTV), complete response, nodal GTV, primary GTV, and performance status. In multivariate analysis, treatment group, TGTV, gender, and primary site were independent prognostic factors for survival. A prognostic threshold of 22.8 cm3 was detected for TGTV. Patients with a TGTV of 22.8 cm3 had a median survival of 12.3 months (log–rank test, p  0.0102).

Conclusion: The prognostic significance of the TGTV was confirmed and a cutoff value of 22.8 cm3 derived. Our data indicated that locally advanced head-and-neck carcinomas should not be treated by standard (once-daily) RT alone. Tumor size and disease subsite should be taken into account in future randomized trials to increase their statistical power. © 2004 Elsevier Inc.

Head-and-neck cancer, Radiotherapy, Chemotherapy, Tumor volume, CT, Prognostic factors.